At a glance
- Originator Taiho Pharmaceutical
- Class Antihyperlipidaemics; Small molecules
- Mechanism of Action Lipase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia; Obesity
Most Recent Events
- 22 May 2001 Profile reviewed but no significant changes made
- 01 Sep 1998 No-Development-Reported for Hyperlipidaemia in Japan (PO)
- 01 Sep 1998 No-Development-Reported for Obesity in Japan (Unknown route)